Our Programs

scientist looking at lab

Platform & Discovery

A MULTI-ASSET, MULTI-INDICATION PIPELINE

Acurex’s foundational intellectual property is built on a breakthrough discovery from Stanford University that established our proprietary Miro1 and Mitophagy Platform. This discovery engine has generated two distinct oral, CNS-penetrant small-molecule programs, each capable of protecting neurons and addressing multiple neurodegenerative indications.

Therapeutic Programs

development pipelinedevelopment pipeline

Program Highlights

CU-13001

  • 15-lipoxygenase Inhibitor
  • Best-in-class
  • Oral, BBB-Penetrant
  • Efficacy in multiple animal models
  • 28-day tox completed
  • New CoM IP
  • SPECT imaging biomarker
  • IND in progress

CU-00048

  • Selective pan-T-type channel antagonist
  • Best-in-class fast follower to ulixcaltamide for the treatment of ET
  • Oral, BBB-penetrant
  • Animal model efficacy
  • New CoM IP
  • IND ready to start

CU-00213

  • First-in-class
  • The only disclosed CaV3.2 selective series
  • Lead optimization